With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.70261-82-4,4-(4-Methylpiperazin-1-ylmethyl)phenylamine,as a common compound, the synthetic route is as follows.
Diethylcyanophosphonate (Aldrich, Buchs, Switzerland; 0.50 mL, 3.0 [MMOL)] is added to a stirred mixture of 3-[[4-(3-pyridinyl)-2-pyrimidinyl] amino] -benzoic acid (438 mg, [1.] 5 [MMOL),] 4- [[ (4-METHYL-1-PIPERAZINYL) METHYL]] benzeneamine (308 mg, 1.5 [MMOL)] and triethylamine (840 [.//L,] 3.0 [MMOL)] in 10 mL N,N-dimethylformamide at [10C.] After stirring for 12 hours at [60C,] the mixture is treated with an aqueous solution of sodium hydrogen carbonate and extracted three times with ethyl acetate. The combined extracts are washed with water, and the solvent is evaporated off under reduced pressure to give a residue. The residue is resuspended in water and filtered to afford the crude product which is recrystallised from tetrahydrofuran- ethyl acetate to give N-[3-[[4-(3-Pyridinyl)-2-pyrimidinyl]amino]-N-[(4-methyl-1-piperazinyl)- methyl] benzamide as a crystalline solid, m. p. [220-224C.], 70261-82-4
70261-82-4 4-(4-Methylpiperazin-1-ylmethyl)phenylamine 3153996, apiperazines compound, is more and more widely used in various fields.
Reference£º
Patent; NOVARTIS AG; NOVARTIS PHARMA GMBH; WO2004/5281; (2004); A1;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics